ClinicalTrials.gg
CompletedNCT04999787Updated Nov 2, 2022

A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus

A Phase 2 interventional study of HSK21542 and Placebo in Pruritus, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 48 studies in Pruritus with a site in China — 18 open to participants now, 20 under way, 4 of them phase 3. Pruritus · China.

Enrollment
24th of 46
90 · median 92
Started
2021
with 2 others
Phase 2
7 of 48
3 open now
Registered
17th of 48
by date
Lead sponsor
3 of 48
Haisco Pharmaceutical Group Co., Ltd.

Among the 48 studies in Pruritus with a site in China, this one is the 24th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 17th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

18 of the 48 studies in Pruritus with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Pruritus with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, double-blind, placebo-controlled study. About 90 liver disease subjects with moderate or above pruritus are planned to be enrolled. They will be randomized to two dose groups (0.3 μg/kg and 0.6 μg/kg) and a placebo control group at a 1:1:1 ratio, with about 30 subjects in each group.

03

Conditions studied

  • Pruritus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 and ≤ 75 years old, male or female;
  2. (BMI): ≥ 18 kg/m2 and ≤ 35 kg/m2;
  3. Suffering from liver diseases with itching, including but not limited to viral hepatitis, liver disease, drug-induced liver disease, alcoholic liver disease, and other liver diseases;
  4. The mean baseline WI-NRS score before randomization suggests moderate to severe itching (≥ 4 points) and the last two WI-NRS scores ≥ 4 points.
  5. Subjects who are willing to sign an form in written form fully understand the objectives and purposes of the study, and are willing to comply with the study protocol before any of the study-related procedures to start.

Exclusion criteria

Exclusion Criteria:

  1. Decompensated hepatic cirrhosis in the following cases:

    1. History of liver transplant, expecting a liver transplant surgery, or the current model for end-stage liver disease (MELD) score ≥ 18;
    2. Grade 3 ascites;
    3. History of gastrointestinal hemorrhage (excluding haemorrhoidal haemorrhage) within one month before randomization;
    4. Hepatic encephalopathy;
  2. Having dermatitis atopic, chronic urticaria, psoriasis or other skin diseases that the investigator determines will disturb the assessment of itching or having itching caused by other diseases.
  3. History of allergy to opioids, such as urticaria;
  4. Cannot ensure the stable use of drugs for the treatment of baseline liver diseases from 4 weeks before the lead-in phase to the end of the follow-up period, such as ursodeoxycholic acid (UCDA), antiviral drugs (excluding interferon), fibrates, etc.;
  5. Cannot ensure the stable use of drugs that may affect the efficacy or safety evaluations from the first 14 days of the lead-in phase to the end of the follow-up period, such as antipsychotics, sedative hypnotics, anxiolytics, antidepressants (excluding selective serotonin reuptake inhibitors), /immunomodulators (such as systemic therapy [excluding topical application], ciclosporin A, azathioprine, methotrexate, etc.);
  6. Using drugs with unclear half-life that may affect the efficacy evaluation within 14 days before the lead-in period, or drugs that affect the efficacy evaluation before randomization, and the last time of use is shorter than 5 half-lives from the lead-in phase (refer to the specific drug labeling), including but not limited to bile acid binding resin (colestyramine, etc.), pregnane X receptor (PXR) agonist (rifampicin, etc.), selective serotonin reuptake inhibitor (SSRIs) (sertraline, etc.), antihistamines, gabapentin, pregabalin, interferon, obeticholic acid or other opioids;
  7. Using the following topical drugs within 3 days before the lead-in phase: antihistamines and glucocorticoids;
  8. Having received traditional Chinese medicine treatment, physical phototherapy or artificial liver treatment that may affect the efficacy evaluation within 14 days before randomization;
  9. Complicated with other serious underlying diseases that the investigator judges may increase the risk of the trial, affect the compliance of the subjects with the protocol or affect the subjects with completion of the trial, including but not limited to malignant tumors (excluding tumors that had been cured [no evidence of disease recurrence within 5 years]), serious cardiovascular and cerebrovascular diseases, mental and neurological disorders, etc.;
  10. Complicated with uncontrolled severe infections (including severe abdominal infection, upper respiratory tract infection, lower respiratory tract infection, urinary system infection, etc.);
  11. Itching secondary to obstruction of bile duct (excluding primary sclerosing cholangitis (PSC));
  12. With the following abnormal laboratory tests results:

    1. \< 30 mL/min/1.73 m2;
    2. Serum total (TBIL) > 15 × ;
    3. > 1.5 × ULN;
    4. Potassium ion concentration \< 3.0 mmol/L;
  13. History of medication or drug abuse and/or alcohol abuse within 3 months prior to screening (alcohol abuse is defined as an average of > 2 units of alcohol consumed per day [1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol, or 150 mL of wine] within 3 months);
  14. Having participated in other clinical trials within 3 months prior to screening (defined as having received drug or placebo);
  15. Positive for (HIV) antibody or syphilis antibody at screening;
  16. Pregnant and breastfeeding females; women of or men who are unwilling to use during the trial; or subjects who are planning pregnancy within 3 months after the completion of the trial (including male subjects);
  17. Expected survival \< 3 months;
  18. Subjects judged by the investigator to have any other factors unsuitable for involvement in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    HSK21542

    HSK21542-0.3 μg/kg,HSK21542-0.6 μg/kg

    Drug: HSK21542

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • HSK21542-0.3 μg/kg,HSK21542-0.6 μg/kg

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Changes in daily Worst Itching Intensity Numerical Rating Scale (WI-NRS) scores from baseline during the administration period

    In the NRS score, 0-10 represents different degrees of itching, the larger the number, the more severe the itching

    Time frame: Day 1 to Day 28

  2. The proportion of subjects whose daily WI-NRS scores improve by ≥ 3 points and ≥ 4 points compared with baseline during the administration period

    Time frame: Day 1 to Day28

  3. Area under curve (AUC) of daily WI-NRS scores during the administration period

    Time frame: Day 1 to Day28

  4. Changes in WI-NRS per unit time (per day) from baseline during the administration period

    Time frame: Day 1 to Day 28

  5. Changes in quality of life (evaluated by Skindex-16 scale) from baseline during the administration period

    Time frame: Day 1 to Day 28

  6. Changes in daily WI-NRS scores from baseline during the follow-up period

    Time frame: Day 29 to Day 31

07

Study locations

1 site
  • The first hospital of Jilin University
    Changchun, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2022, 10 months.

Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 10 months is below that.

Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 11, 2021
StartActual
Sep 16, 2021
Primary completionActual
Aug 3, 2022
CompletionActual
Aug 3, 2022
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04999787
Responsible party
Sponsor
First posted
Aug 11, 2021
Start date
Sep 16, 2021
Primary completion
Aug 3, 2022
Completion
Aug 3, 2022
Last update
Nov 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anrikefon

Start the discussion